Acinetobacter baumannii Is an opportunistic pathogen as an MDRO especially on intensive ward

I Wayan Suranadi, Ni Nengah Dwi Fatmawati, I Wayan Aryabiantara, Cynthia Dewi Sinardja, Darmawan Jaya Saputra

I Wayan Suranadi
Udayana University

Ni Nengah Dwi Fatmawati
Udayana University

I Wayan Aryabiantara
Udayana University

Cynthia Dewi Sinardja
Udayana University

Darmawan Jaya Saputra
Udayana university. Email:
Online First: August 30, 2019 | Cite this Article
Suranadi, I., Dwi Fatmawati, N., Aryabiantara, I., Sinardja, C., Saputra, D. 2019. Acinetobacter baumannii Is an opportunistic pathogen as an MDRO especially on intensive ward. Bali Journal of Anesthesiology 3(2). DOI:10.15562/bjoa.v3i2.199

Acinetobacter baumannii is an opportunistic bacterial pathogen that is associated with hospital acquired infections and is a major cause of nosocomial infections especially in intensive spaces; this is becoming increasingly a widespread concern in various hospitals around the world. Acinetobacter baumannii, which is resistant to many antibiotics, is now recognized as clinically very important. Reports suggest that the spread of A. baumannii in the hospital environment led to an increase in nosocomial outbreaks associated with high mortality rates. However, many other Acinetobacter spp. can also cause nosocomial infections. This review focuses on the role of Acinetobacter spp. as nosocomial pathogens, resistance patterns and epidemiology.


Jung, J., Park, W., 2015. Acinetobacter species as model microorganisms in environmental microbiology: current state and perspectives. Appl. Microbiol. Biotechnol. 99, 2533–2548.

Vaneechoutte, M., D. M. Young, L. N. Ornston, T. De Baere, A. Nemec, T. Van Der Reijden, E. Carr, I. Tjernberg, and L. Dijkshoorn. 2006. Naturally transformable Acinetobacter sp. strain ADP1 belongs to the newly described species Acinetobacter baylyi. Appl. Environ. Microbiol. 72:932–936.

Glew, R. H., R. C. Moellering, Jr., and L. J. Kunz. 1977. Infections with Acinetobacter calcoaceticus (Herellea vaginicola): clinical and laboratory studies. Medicine (Baltimore) 56:79–97.

Bergogne-Berezin, E., and K. J. Towner. 1996. Acinetobacter spp. as noso- comial pathogens: microbiological, clinical, and epidemiological features. Clin. Microbiol. Rev. 9:148–165.

Rossau, R., A. van Landschoot., M. Gillis, and J. de Ley. 1991. Taxonomy of Moraxellaceae fam. nov., a new bacterial family to accomodate the genera Moraxella, Acinetobacter, and Psychrobacter and related organisms. Int. J. Syst. Bacteriol. 41:310–319.

Baumann P, Doudoroff M, Stanier RY. A study of the Moraxella group. II. Oxidative-negative species (genus Acinetobacter). J Bacteriol 1968; 95:1520-41; PMID: 5650064

Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006; 42:692-9; PMID:16447117; http://

Sebeny PJ, Riddle MS, Petersen K. Acinetobacter baumannii skin and soft-tissue infection associated with war trauma. Clin Infect Dis 2008; 47:444-9; PMID: 18611157;

Choi CH, Lee EY, Lee YC, Park TI, Kim HJ, Hyun SH, et al. Outer membrane protein 38 of Acinetobacter baumannii localizes to the mitochondria and induces apoptosis of epithelial cells. Cell Microbiol 2005; 7:1127-38; PMID:16008580; 1111/j.1462-5822.2005.00538.x

Gaddy JA, Actis LA. Regulation of Acinetobacter baumannii biofilm formation. Future Microbiol 2009; 4:273-8; PMID:19327114; fmb.09.5

Kim SW, Choi CH, Moon DC, Jin JS, Lee JH, Shin JH, et al. Serum resistance of Acinetobacter baumannii through the binding of factor H to outer membrane proteins. FEMS Microbiol Lett 2009; 301:224-31; PMID:19878322; 6968.2009.01820.x

Jacobs AC, Hood I, Boyd KL, Olson PD, Morrison JM, Carson S, et al. Inactivation of phospholipase D diminishes Acinetobacter baumannii pathogenesis. Infect Immun 2010; 78:1952-62; PMID:20194595; http://

Camarena L, Bruno V, Euskirchen G, Poggio S, Snyder M. Molecular mechanisms of ethanol-induced patho- genesis revealed by RNA-sequencing. PLoS Pathog 2010; 6:e1000834; PMID:20368969; http://dx.doi. org/10.1371/journal.ppat.1000834

Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21:538-82; PMID:18625687;

Hujer KM, Hamza NS, Hujer AM, Perez F, Helfand MS, Bethel CR, et al. Identification of a new allelic variant of the Acinetobacter baumannii cephalospori- nase, ADC-7 beta-lactamase: defining a unique family of class C enzymes. Antimicrob Agents Chemother 2005; 49:2941-8; PMID:15980372; 10.1128/AAC.49.7.2941-2948.2005

Corvec S, Caroff N, Espaze E, Giraudeau C, Drugeon H, Reynaud A. AmpC cephalosporinase hyperproduc- tion in Acinetobacter baumannii clinical strains. J Antimicrob Chemother 2003; 52:629-35; PMID: 12951337;

Grupper M, Sprecher H, Mashiach T, Finkelstein R. Attributable mortality of nosocomial Acinetobacter bacteremia. Infect Control Hosp Epidemiol 2007; 28:293-8; PMID:17326019; 1086/512629

Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007; 13:97-103; PMID:17370521; (52)

Luna CM, Aruj PK. Nosocomial Acinetobacter pneu- monia. Respirology 2007; 12:787-91; PMID:17986104;

Anstey NM, Currie BJ, Hassell M, Palmer D, Dwyer B, Seifert H. Community-acquired bacteremic Acinetobacter pneumonia in tropical Australia is caused by diverse strains of Acinetobacter baumannii, with carriage in the throat in at-risk groups. J Clin Microbiol 2002; 40:685-6; PMID: 11825997; 686.2002

Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-17; PMID:15306996; http://dx.doi. org/10.1086/421946

Metan G, Alp E, Aygen B, Sumerkan B. Acinetobacter baumannii meningitis in post-neurosurgical patients: clinical outcome and impact of carbapenem resistance. J Antimicrob Chemother 2007; 60:197-9; PMID: 17540668;

Jain, R., Danziger, L.H., 2004. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann. Pharmacother. 38, 1449–1459.

Manchanda, V., Sanchaita, S., Singh, N., 2010. Multidrug resistant acinetobacter. J. Global Infect. Dis. 2, 291.

Dinc, G., Demiraslan, H., Elmali, F., Ahmed, S.S., Alp, E., Doganay, M., 2015. Antimicrobial efficacy of doripenem and its combinations with sulbactam, amikacin, colistin, tigecycline, inexperimental sepsis of carbapenem-resistant Acinetobacter baumannii. N. Microbiol. 38, 67–73.

Eliopoulos, G.M., Maragakis, L.L., Perl, T.M., 2008. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin. Infect. Dis. 46, 1254–1263.

Yadav, R., Landersdorfer, C.B., Nation, R.L., Boyce, J.D., Bulitta, J. B., 2015. Novel approach to optimize synergistic carbapenem- aminoglycoside combinations against carbapenem-resistant Acine- tobacter baumannii. Antimicrob. Agents Chemother. 59, 2286– 2298.

Vourli, S., Frantzeskaki, F., Meletiadis, J., Stournara, L., Armagani- dis, A., Zerva, L., Dimopoulos, G., 2015. Synergistic interactions between colistin and meropenem against extensively drug-resistant and pandrug-resistant Acinetobacter baumannii isolated from ICU patients. Int. J. Antimicrob. Agents.

No Supplementary Material available for this article.
Article Views      : 394
PDF Downloads : 243